Astrazeneca (AZN) Cash & Equivalents (2009 - 2026)
Astrazeneca's Cash & Equivalents came in at $4.89 billion for Q2 2026, down 30.7% from $7.06 billion a year earlier and down 35.3% from the prior quarter.
Powered by 
Analysis
Astrazeneca (AZN) Cash & Equivalents (2009 - 2026) Analysis & Trends
At the end of FY2025, Astrazeneca's Cash & Equivalents was $5.71 billion, up 4.1% from FY2024.
- Cash & Equivalents carries a five-year compound annual growth rate of -6.1% (FY2020 to FY2025).
- Going back by year, Cash & Equivalents was $5.49 billion in FY2024 (-6.0%), $5.84 billion in FY2023 (-5.3%), $6.17 billion in FY2022 (-2.6%) and $6.33 billion in FY2021 (-19.2%).
- The Q2 2026 figure represents the lowest quarterly Cash & Equivalents since Q3 2024.
- Year-over-year, Cash & Equivalents increased in four of the last eight quarters, with growth averaging 6.1%.
- The fastest year-over-year change in Cash & Equivalents over five years came in Q3 2025 (growth of 69.8%), and the weakest in Q2 2022 (a decline of 69.1%).
- Business Quant data shows AZN's Cash & Equivalents at $7.56 billion (Q1 2026), $5.71 billion (Q4 2025) and $8.14 billion (Q3 2025) in the three quarters before Q2 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,109.58 Bn | 1,078.16 Bn | 19.71 Bn | 8.95 Bn |
| 2 | Johnson & Johnson | 630.16 Bn | 548.69 Bn | 17.26 Bn | 20.42 Bn |
| 3 | AbbVie | 488.57 Bn | 461.73 Bn | 12.70 Bn | 6.57 Bn |
| 4 | Merck | 359.15 Bn | 313.58 Bn | 12.21 Bn | 6.85 Bn |
| 5 | Novartis Ag | 274.32 Bn | 238.71 Bn | 11.24 Bn | 7.62 Bn |
| 6 | Astrazeneca | 246.73 Bn | 220.50 Bn | 12.86 Bn | 4.89 Bn |
| 7 | Amgen | 224.28 Bn | 179.68 Bn | 7.24 Bn | 13.99 Bn |
| 8 | Gilead Sciences | 187.60 Bn | 161.71 Bn | 6.22 Bn | 3.18 Bn |
| 9 | Pfizer | 161.13 Bn | 108.08 Bn | 10.94 Bn | 976.00 Mn |
| 10 | Vertex Pharmaceuticals | 129.23 Bn | 101.23 Bn | 2.84 Bn | 6.14 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 4.89 Bn |
| Mar 31, 2026 | 7.56 Bn |
| Dec 31, 2025 | 5.71 Bn |
| Sep 30, 2025 | 8.14 Bn |
| Jun 30, 2025 | 7.06 Bn |
| Mar 31, 2025 | 5.23 Bn |
| Dec 31, 2024 | 5.49 Bn |
| Sep 30, 2024 | 4.80 Bn |
| Jun 30, 2024 | 6.92 Bn |
| Mar 31, 2024 | 7.84 Bn |
| Dec 31, 2023 | 5.84 Bn |
| Sep 30, 2023 | 4.87 Bn |
| Jun 30, 2023 | 5.66 Bn |
| Mar 31, 2023 | 6.23 Bn |
| Dec 31, 2022 | 6.17 Bn |
| Sep 30, 2022 | 4.46 Bn |
| Jun 30, 2022 | 4.82 Bn |
| Mar 31, 2022 | 5.76 Bn |
| Dec 31, 2021 | 6.33 Bn |
| Sep 30, 2021 | 7.07 Bn |
API Access
Astrazeneca Cash & Equivalents API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=AZN&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "cash-and-equivalents", "ticker": "AZN", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=AZN&period=max&api_key=YOUR_API_KEY");
const data = await res.json();